Valeant slashed its guidance for the current quarter and provided preliminary results for its final quarter of the year short of Wall Street estimates on softer-than-expected sales in the gastrointestinal business.
from WSJ.com: US Business http://ift.tt/1nKRxjP
via IFTTT
No comments:
Post a Comment